1. Figure 3 Intracranial targeting of high-grade gliomas
by the tumour-specific ABT-806, the parental antibody of ABT-414
Figure 3 | Intracranial targeting of high-grade gliomas by the tumour-specific ABT-806, the parental antibody of ABT-414. a | Single-photon emission computed tomography (SPECT)/CT images and quantification of uptake of 111In-ABT-806 in mice with intracranial U87MGde2-7 tumour implants, which overexpress wild-type EGFR and EGFRvIII. Reprinted from Reilly, E. B. et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol. Cancer Ther. 14, 1141–1151 (2015), with permission from AACR. b | Uptake of 111In-labelled chimeric 806 (the chimeric version of ABT-806) in a patient with high-grade glioma in the right frontal lobes showing blood pool activity only in panel i, followed by increasing uptake by days 3 (arrow in panel ii) and 7 (iii). The uptake is confirmed on axial SPECT imaging (arrow in panel iv) to be at the site of 18F-FDG uptake (v) and the structural abnormality on T1 MRI (vi). Reproduced from Scott, A. M. et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl Acad. Sci. USA 104, 4071–4076 (2007), copyright (2007) National Academy of Sciences, U.S.A.
Proc. Natl Acad. Sci. USA 104, 4071–4076 (2007), copyright (2007) National Academy of Sciences, U.S.A.
Gan, H. K. et al. (2017) Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells
Nat. Rev. Clin. Oncol. doi: /nrclinonc